UG United Guardian Inc

UNITED-GUARDIAN, INC.

 

Part I. FINANCIAL INFORMATION

 

ITEM 1. Condensed Financial Statements

 

STATEMENTS OF INCOME
(unaudited)

 

 

 

 

See Notes to Condensed Financial Statements

 

 

UNITED-GUARDIAN, INC.

 

BALANCE SHEETS

 

 

 

 

 

 

See Notes to Condensed Financial Statements

 

 

UNITED-GUARDIAN, INC.

 

BALANCE SHEETS

(continued)

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

See Notes to Condensed Financial Statements

 

 

 

UNITED-GUARDIAN, INC.

 

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(unaudited)

 

 

THREE AND SIX MONTHS ENDED JUNE 30, 2024

 

 

 

 

THREE AND SIX MONTHS ENDED JUNE 30, 2023

 

 

 

 

 

See Notes to Condensed Financial Statements

 

 

 

UNITED-GUARDIAN, INC.

STATEMENTS OF CASH FLOWS
(unaudited)

 

 

 

 

See Notes to Condensed Financial Statements

 

 

UNITED-GUARDIAN, INC.

 

NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited)

 

1.	Nature of Business

 

United-Guardian, Inc. (“Registrant” or “Company”) is a Delaware corporation that, through its Guardian Laboratories division, manufactures and markets cosmetic ingredients, pharmaceutical products, medical lubricants, and sexual wellness ingredients. Prior to July 1, 2023, the Company manufactured and reported sales of a line of specialty industrial products; however, this product line was discontinued after the second quarter of 2023 due to low sales volume with no growth prospects. The Company conducts research and product development leading to commercialization of new premium ingredients for cosmetics and healthcare products. The Company’s research and development department also modifies, refines, and expands the uses for existing products, with the goal of further developing the market for its products. The Company is developing new products using natural and environmentally friendly raw materials, which is a priority for many of the Company’s cosmetic customers.

 

2.	Basis of Presentation

 

Interim condensed financial statements of the Company are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information, pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments considered necessary for the fair presentation of financial statements for the interim periods have been included. The results of operations for the three and six months ended June 30, 2024 (also referred to as the "second quarter of 2024" and the "first half of 2024", respectively) are not necessarily indicative of results that ultimately may be achieved for any other interim period or for the year ending December 31, 2024. The interim unaudited condensed financial statements and notes thereto should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

 

3.	Impact of Global Supply Chain Instability and Inflation

 

The continued supply chain instability, primarily caused by military conflicts in the Middle East, has impacted vessels’ access to the Red Sea and Suez Canal. The Company is working closely with its suppliers regarding lead times and continues to closely monitor this situation. Although the Company has not experienced any delays in receiving raw materials or a substantial increase in shipping costs, we are aware that the situation is fluid and could impact the Company at any time. If that occurs, we may experience longer lead times and increased shipping costs for some of the Company’s raw materials, which may impact the Company’s future gross margins.

 

As a result of this global supply chain instability and higher interest rates, there continues to be uncertainty regarding the potential impact on the Company’s operations and financial results and we are unable to provide an accurate estimate or projection as to what the future impact will be.

 

4.	Use of Estimates

 

In preparing financial statements in conformity with Generally Accepted Accounting Principles in the United States of America (“US GAAP”), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for credit losses, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocation of overhead.

 

 

7 of 22

---

 

  

5.	Cash and Cash Equivalents

 

For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at the time of purchase. The Company deposits cash and cash equivalents with financially strong, FDIC-insured financial institutions, and believes that any amounts above FDIC insurance limitations are at minimal risk. The amounts held in excess of FDIC limits at any point in time are considered temporary and are primarily due to the timing of the maturities of United States Treasury Bills. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At June 30, 2024 and December 31, 2023, $506,000 and $315,000, respectively, exceeded the FDIC limit.

 

Cash and cash equivalents include currency on hand, demand deposits with banks or financial institutions, and short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. The following table summarizes the Company's cash and cash equivalents:

 

		June 30,				December 31,
		2024				2023
Demand Deposits		$	1,181,655			$	340,034
Certificates of Deposit (original maturities of < 3 months)			-				125,000
Money Market Funds			178,770				1,031,361
U.S. Treasury Bills (original 3-month maturity)			7,044,946				6,746,727
Total Cash and Cash Equivalents		$	8,405,371			$	8,243,122

 

 

6.	Accounts Receivable and Reserves

 

As of January 1, 2023, the Company adopted FASB Accounting Standards Update (“ASU”) No. 2016-13, Measurement of Credit Losses on Financial Instruments, and all subsequently issued related amendments, which changed the methodology used to recognize impairment of the Company’s contract receivables. Under this ASU, financial assets are presented at the net amount expected to be collected, requiring immediate recognition of estimated credit losses expected to occur over the asset’s remaining life. This is in contrast to previous US GAAP, under which credit losses were not recognized until it was probable that a loss had been incurred. The Company performed its expected credit loss calculation based on historical accounts receivable write-offs, including consideration of then-existing economic conditions and expected future conditions. The adoption of this ASU did not have a significant impact on the financial statements. Prior to the implementation of ASU No. 2016-13, the Company calculated its reserve for accounts receivable by considering many factors including historical data, experience, customer types, credit worthiness and economic trends.

 

The carrying amount of accounts receivable is reduced by an allowance for credit losses that reflects the Company’s best estimate of the amounts that will not be collected as of the balance sheet date. This allowance is based on the credit losses expected to arise over the life of the asset and is based on the Current Expected Credit Losses (“CECL”). At June 30, 2024, and December 31, 2023, the allowance for credit losses related to accounts receivable amounted to $20,241 and $16,672, respectively.

 

 

8 of 22

---

 

  

7.	Revenue Recognition

 

The Company records revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales.

 

As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, the Company recognizes revenue from sales of its products when those products are shipped, which is when the Company’s performance obligation is satisfied. The Company’s cosmetic ingredients are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of the Company’s non-pharmaceutical medical products are deemed final upon shipment, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective. Sales of the Company’s pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product cannot be sold because it is too close to its expiration date; or (d) the product has expired (but it is not more than one year after the expiration date). This return policy conforms to standard pharmaceutical industry practice. The Company estimates an allowance for outdated material returns based on previous years’ historical returns of its pharmaceutical products.

 

The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period that the revenues are recognized. Such deductions, primarily related to sales of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with the Company’s participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.

 

During 2024 and 2023, the Company participated in various government drug rebate programs related to the sale of Renacidin®, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (FSS), and the Medicare Part D Coverage Gap Discount Program (CGDP). These programs require the Company to sell its product at a discounted price. The Company’s sales, as reported, are net of these product rebates and discounts, some of which are estimated and are recorded in the same period that the revenue is recognized.

 

In August of 2022, the Inflation Reduction Act (“IRA”) was signed into law. The IRA made significant changes to the current Medicare Part D benefit design as it relates to discounts available to enrollees from pharmaceutical manufacturers of brand name drugs. Beginning on January 1, 2025, the Centers for Medicare & Medicaid Services (“CMS”) will implement a new Medicare Part D Manufacturer Discount Program (“discount program”), which will replace the current CGDP. The new discount program eliminates the coverage gap benefit phase, introduces pharmaceutical manufacturer discounts in the initial and catastrophic coverage phases and lowers the cap on enrollee out-of-pocket costs. Under the new discount program, additional rebates are expected to be owed by pharmaceutical manufacturers due to the restructuring of the benefit periods. The overall financial impact of this new program will vary depending on the products being reimbursed but does have the potential to increase Medicare Part D rebates for drug manufacturers. At this time, the Company is unable to predict what future impact this new program will have on its financial condition; however, on January 31, 2024, the Company was notified by CMS that it qualified as a “specified small manufacturer” and will be entitled to a multi-year phase-in period during which it will pay a lower percentage discount on drugs dispensed to beneficiaries.

 

The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party.

 

Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606. At June 30, 2024 and December 31, 2023, the Company had an allowance of $268,242 and $247,847, respectively, for possible outdated material returns, which is included in accrued expenses. There is no asset value associated with these outdated material returns, as these products are destroyed.

 

9 of 22

---

 

 

As of December 31, 2023, the Company recorded advance payments from customers of $15,498, which were included in deferred revenue on the balance sheet. The related performance obligations associated with these payments were satisfied in the first quarter of 2024. There were no such advance payments as of June 30, 2024.

 

The Company has distribution fee contracts with certain distributors of its pharmaceutical products that entitle them to distribution and service-related fees. The Company records distribution fees and estimates of distribution fees as offsets to revenue.

 

Disaggregated sales by product class are as follows:

 

 

		Three months ended								Six months ended
		June 30,								June 30,
		2024				2023				2024				2023
Cosmetic ingredients		$	1,419,374			$	772,887			$	3,295,856			$	1,534,788
Pharmaceuticals			1,413,664				1,376,601				2,363,987				2,730,825
Medical lubricants			557,167				482,512				985,306				903,543
Industrial products (1)			-				18,299				-				51,467
Total Net Sales		$	3,390,205			$	2,650,299			$	6,645,149			$	5,220,623

 

          _{(1) This product line was discontinued as of July 1, 2023.}

 

The Company’s cosmetic ingredients are marketed worldwide by five distributors, of which U.S.-based Ashland Specialty Ingredients (“ASI”) purchases the largest volume. Approximately 17% of the Company’s total sales in the second quarter of 2024 were to customers located outside of the United States, compared with approximately 22% in the second quarter of 2023. For the six months ended June 30, 2024, approximately 15% of the Company’s total sales were to customers located outside of the United States, compared with approximately 23% for the six months ended June 30, 2023.

 

Disaggregated sales by geographic region are as follows:

 

		Three months ended								Six months ended
		June 30,								June 30,
		2024				2023				2024				2023
United States*		$	2,808,237			$	2,067,533			$	5,627,173			$	4,009,775
Other countries			581,968				582,766				1,017,976				1,210,848
Total Sales		$	3,390,205			$	2,650,299			$	6,645,149			$	5,220,623

 

 

* Since substantially all purchases by ASI are shipped to ASI’s warehouses in the U.S., all sales to ASI are reported as U.S. sales for financial reporting purposes, even though a significant quantity of those purchases will be shipped by ASI to foreign customers. ASI has reported to the Company that approximately 85% of its sales of the Company’s products in the second quarter of 2024 were to foreign customers, with China representing approximately 56%. For the same time period in 2023, approximately 65% of ASI’s sales of the Company’s products were to foreign customers, with China representing approximately 35%.

 

For the six months ended June 30, 2024 approximately 84% of ASI’s sales of the Company’s products were to customers in other countries, with China accounting for approximately 50% of ASI’s sales of the Company’s products, as compared with approximately 68% of ASI’s sales going to customers in other countries for the six months ended June 30, 2023, with China accounting for approximately 29% of ASI’s sales of the Company’s products during that period.

 

10 of 22

---

 

  

8.	Accounting for Financial Instruments – Credit Losses

 

The Company recognizes an allowance for credit losses for its trade receivables to present the net amount expected to be collected as of the balance sheet date. This allowance is based on the credit losses expected to arise over the life of the asset and are based on Current Expected Credit Losses (CECL).

 

The timing between recognition of revenue for product sales and the receipt of payment is not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. The Company provides allowances for any receivables for which collection is doubtful in accordance with ASU 2016-13. As of June 30, 2024 and December 31, 2023, the allowance for credit losses on accounts receivable was $20,241 and $16,672, respectively. Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded only after they have been taken.

 

9.	Marketable Securities

 

The Company’s marketable securities include investments in equity mutual funds and Certificates of Deposit with maturities longer than three months. The Company’s marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. Certificates of Deposit are recorded at amortized cost. Realized gains or losses on mutual funds are determined on a specific identification basis. The Company evaluates its investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and the Company’s ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery of market value.

 

The disaggregated net gains and losses on marketable securities that were recognized on the income statements for the three and six months ended June 30, 2024 and June 30, 2023 were as follows:

 

		THREE MONTHS ENDED JUNE 30,								SIX MONTHS ENDED JUNE 30,
		2024				2023				2024				2023
Net (losses) gains recognized during the period on marketable securities		$	(9,501	)		$	7,479			$	31,995			$	80,180
Less: Net losses recognized on marketable securities sold during the period			-				(433,769	)			-				(433,769	)
Unrealized (losses) gains recognized during the reporting period on marketable securities still held at the reporting date		$	(9,501	)		$	441,248			$	31,995			$	513,949

 

The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows:

 

•    Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

11 of 22

---

 

 

•    Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

•    Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

The Company’s marketable equity securities, which are considered available for sale securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets. The Company’s fixed income Certificates of Deposit are considered held-to-maturity securities and are valued at amortized cost.

 

The following tables summarize the Company’s investments:

 

June 30, 2024 (unaudited)										Unrealized
		Cost				Fair value				gain
Equity and other mutual funds		$	583,103			$	617,086			$	33,983
Other short-term investments:
Fixed income Certificates of Deposit (original maturities >3 months)			836,456				836,456				-
Total marketable securities		$	1,419,559			$	1,453,542			$	33,983

                                   

December 31, 2023 (audited)										Unrealized
		Cost				Fair Value				gain
Equity Securities
Equity and other mutual funds		$	574,330			$	576,318			$	1,988
Other short-term investments:
Fixed income Certificates of Deposit (original maturities >3 months)			275,000				275,000				-
Total marketable securities		$	849,330			$	851,318			$	1,988

 

Investment income is recognized when earned and consists principally of dividend income from equity mutual funds and interest income from United States Treasury Bills, Certificates of Deposit and money market funds. Realized gains and losses on sales of investments are determined on a specific identification basis.

 

Proceeds from the sale and redemption of marketable securities amounted to $775,000 for the first half of 2024, and there were no realized gains or losses recognized on these sales. Proceeds from the sale and redemption of marketable securities amounted to $5,255,145 for the first half of 2023, which included realized losses on sales of $433,769.

 

10.	Inventories

 

		June 30,				December 31,
		2024				2023
		(unaudited)				(audited)
Inventories consist of the following:
Raw materials		$	587,938			$	476,501
Work in process			74,409				92,089
Finished products			509,740				654,916
Total inventories		$	1,172,087			$	1,223,506

 

12 of 22

---

 

 

Inventories are valued at the lower of cost and net realizable value. Net realizable value is equal to the selling price less the estimated costs of selling and/or disposing of the product. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Finished product inventories at June 30, 2024 and December 31, 2023 are stated net of a reserve of $25,000 and $47,000, respectively, for slow moving and obsolete inventory.

 

11.	Income Taxes

 

The Company’s tax provision is based on its estimated annual effective tax rate. The Company continues to fully recognize its tax benefits, and as of June 30, 2024 and December 31, 2023, the Company did not have any unrecognized tax benefits. The Company’s provision for income taxes for the three and six months ended June 30, 2024 and 2023, included the following:

 

		Three months ended								Six months ended
		June 30,								June 30,
		2024				2023				2024				2023
Provision for (benefit from) federal income taxes - current		$	302,100			$	(81,601	)		$	472,040			$	164,778
Provision for state income taxes - current			-				-				225				250
(Benefit from) provision for federal income taxes - deferred			(53,141	)			201,006				17,428				150,453
Total provision for income taxes		$	248,959			$	119,405			$	489,693			$	315,481

  

12.	Defined Contribution Plan

 

The Company sponsors a 401(k) defined contribution plan (“DC Plan”) that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee’s pay that is deferred by the employee. Employees become fully vested in employer matching contributions immediately.

 

The Company also makes discretionary contributions to each employee's account based on a "pay-to-pay" safe-harbor formula that qualifies the 401(k) Plan under current IRS regulations. Employees become vested in the discretionary contributions as follows: 20% after two years of employment, and 20% for each year of employment thereafter until the employee becomes fully vested after six years of employment.

 

The Company accrued $54,500 in contributions to the DC Plan for the six months ended June 30, 2024 and 2023, respectively. In the first six months of 2024 and 2023, the Company made discretionary contributions of $109,000 and $94,326, respectively, to the DC Plan. These payments represented the Company’s 2023 and 2022 accrued discretionary contributions, respectively.

 

13.	Other Information

 

		June 30,				December 31,
Accrued Expenses		2024 (unaudited)				2023 (audited)
Bonuses		$	105,000			$	187,002
Distribution fees			432,602				407,133
Payroll and related expenses			118,356				96,157
Reserve for outdated material			268,242				247,847
Company 401(k) contribution			54,500				109,000
Audit fee			42,128				71,000
Annual report expenses			40,623				81,725
Sales rebates			220,764				132,250
Insurance			42,272				-
Other			30,266				30,930
Total accrued expenses		$	1,354,753			$	1,363,044

 

13 of 22

---

 

 

 

14.	Recent Accounting Pronouncements

 

In December 2023, the FASB issued ASU 2023-09 “Income Taxes- Improvements to Income Tax Disclosures”. This guidance enhances the transparency and decision usefulness of income tax disclosures. More specifically, the amendments relate to the income tax rate reconciliation and income taxes paid disclosures and require 1) consistent categories and greater disaggregation of information in the rate reconciliation and 2) income taxes paid disaggregated by jurisdiction. This guidance is effective for fiscal years beginning after December 31, 2024.

 

15.	Concentrations of Credit Risk

 

Customer Concentration: Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether any credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its credit risk from accounts receivable has been reduced.

 

During the three months ended June 30, 2024, the Company’s largest cosmetic ingredient distributors and three of its pharmaceutical distributors, accounted for 82% of the Company’s gross sales, and 83% of its outstanding accounts receivable at June 30, 2024. During the three months ended June 30, 2023, the same cosmetic ingredient distributor and three pharmaceutical distributors accounted for 72% of the Company’s gross sales and 82% of its outstanding accounts receivable at June 30, 2023.

 

During the six months ended June 30, 2024, the Company’s largest cosmetic ingredient distributors, along with three of its pharmaceutical distributors, accounted for 82% of the Company’s gross sales and 83% of its outstanding accounts receivable at June 30, 2024. During the six-month period ended June 30, 2023, the same cosmetic ingredient distributor and three pharmaceutical distributors accounted for 73% of the Company’s gross sales and 82% of its outstanding accounts receivable at June 30, 2023.

 

16.	Supplier Concentration

 

Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals that available in ample supply from numerous sources. However, there are some raw materials used by the Company that are not readily available or require longer lead times.

 

During the first half of 2024 and 2023, the Company had three major raw material suppliers that collectively accounted for approximately 79% and 80%, respectively, of the raw material purchases made by the Company. For the three months ended June 30, 2024, the Company had three major raw material suppliers that collectively accounted for approximately 83% of the raw material purchases made by the Company. For the three months ended June 30, 2023, the Company had two major raw material suppliers that collectively accounted for approximately 89% of the raw material purchases made by the Company. In addition to the Company’s raw materials concentration, the Company utilizes one contract manufacturer for the production of its pharmaceutical product, Renacidin. Any disruption in this manufacturer’s operations could have a material impact on the Company’s revenue stream.

 

14 of 22

---

 

  

17.	Related-Party Transactions

 

For the three- and six-month periods ended June 30, 2024, the Company made payments of $10,000 and $20,000, respectively, to Ken Globus, the Company’s former President, for consulting services provided to the Company. For the three- and six-month periods ended June 30, 2023, the Company made payments of $30,000 and $60,000, respectively, to Ken Globus for consulting services.

 

For the three- and six-month periods ended June 30, 2024, the Company made payments of $5,250 and $10,750, respectively, to the accounting firm PKF O’Connor Davies (“PKF”) for accounting and tax services. For the three- and six-month periods ended June 30, 2023, the Company made payments of $3,000 to the accounting firm PKF, for accounting and tax services. Lawrence Maietta, a partner at PKF, is a director of the Company.

 

18.	Earnings Per Share

 

Basic earnings per share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period, increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued.

 

Per share basic and diluted earnings amounted to $0.21 and $0.10 for the three months ended June 30, 2024 and 2023, respectively, and $0.41 and $0.26 for the six months ended June 30, 2024 and 2023, respectively.

 

19.

Dividends

 

On January 30, 2024, the Company’s Board of Directors declared a cash dividend of $0.25 per share, which was paid on February 20, 2024, to all holders of record as of February 12, 2024. During the first half of 2024, the Company declared a total of $1,148,580 in dividends, of which $1,148,468 was paid. The balance of $112 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. There were no dividends declared or paid in the first half of 2023.

 

20.	Subsequent Events

 

On July 10, 2024, the Company’s Board of Directors declared a cash dividend of $0.35 per share, which was paid on July 31, 2024, to all holders of record as of July 23, 2024. Dividends totaling $1,607,855 were paid on July 31, 2024, leaving a balance of $156 that was not paid. This $156 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.

 

Item 2.          Management's Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis cover material changes in the financial condition of the Company since the year ended December 31, 2023, and a comparison of the results of operations for the second quarter of 2024 and 2023 and the first half of 2024 and 2023. This discussion and analysis should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. All references in this quarterly report to “sales” or “Sales” shall mean “net sales” unless specifically identified as “gross sales”.

 

FORWARD-LOOKING STATEMENTS

 

Statements made in this Form 10-Q which are not purely historical are forward-looking statements with respect to the goals, plans, objectives, intentions, expectations, financial condition, results of operations, future performance, and business of the Company. Forward-looking statements may be identified by the use of such words as “believes”, “may”, “will”, “should”, “intends”, “plans”, “estimates”, “anticipates”, or other similar expressions. Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are

 

 

beyond the Company’s control) could cause actual results to differ materially from those set forth in the forward-looking statements. In addition to those specific risks and uncertainties set forth in the Company's reports currently on file with the SEC, some other factors that may affect the future results of operations of the Company are: the development of products that may be superior to those of the Company; changes in the quality or composition of the Company's products; lack of market acceptance of the Company's products; the Company's ability to develop new products; general economic or industry conditions; changes in intellectual property rights; changes in interest rates; new legislation or regulatory requirements; conditions of the securities markets; the Company's ability to raise capital; changes in accounting principles, policies or guidelines; financial or political instability; acts of war or terrorism; and other economic, competitive, governmental, regulatory and technical factors that may affect the Company's operations, products, services and prices. Accordingly, results achieved may differ materially from those anticipated as a result of such forward-looking statements, and those statements speak only as of the date they are made.

 

The Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.

 

OVERVIEW

 

The Company is a Delaware corporation that, through its Guardian Laboratories division, manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness products. Prior to July 1, 2023, the Company manufactured and reported sales of a line of specialty industrial products; however, this product line was discontinued after the second quarter of 2023 due to low sales volume with no growth prospects. In October 2023, the Company entered into an agreement with Brenntag Specialties, a global market leader in chemicals and ingredients distribution, for the marketing of the Company’s new line of sexual wellness ingredients, specifically called the “Natrajel®” line of products, in the United States, Canada, Mexico, Central America and South America. Although there were no sales of these products during 2023, the Company anticipates that it will begin manufacturing and reporting sales of this new line of products in the second half of 2024.

 

The Company also conducts research and product development. The Company’s research and development department also modifies, refines, and expands the uses for existing products, with the goal of further developing the market for its products. The Company also develops new products using natural and environmentally friendly raw materials, which is a priority for many of the Company’s cosmetic customers. All the products that the Company markets, except for Renacidin, are produced at its facility in Hauppauge, New York. Renacidin, a urological product, is manufactured and packaged for the Company by an outside contract manufacturer.

 

The Company’s most important product line is its Lubrajel® line of multifunctional hydrogels, which are designed to provide sensory enhancement, lubrication, and texture to both personal care and medical products.

 

The Company’s cosmetic ingredients are marketed worldwide for cosmetic uses by five distributors, each handling a different geographic area, with the largest being U.S.-based ASI. In the last few years, to meet the growing demand for “green” and sustainable products, the Company has focused on developing and launching new products which only contain ingredients that are considered “natural”. The Lubrajel products in the new natural line have been certified by the Cosmetic Organic and Natural Standard (“COSMOS”). This standard is recognized globally by the cosmetic industry.

 

Renacidin and the Company’s other pharmaceutical product, Clorpactin® WCS-90, are distributed through full-line drug wholesalers and marketed only in the United States. Those wholesalers in turn sell the products to pharmacies, hospitals, nursing homes, and other long-term care facilities, and to government agencies, primarily the VA. The Company promotes Renacidin through a dedicated website. Clorpactin WCS-90, as well as the Company’s other products, are marketed through information provided on the Company’s corporate website.

 

The Company’s medical lubricants, which consist of multifunctional hydrogels designed mainly to provide sensory enhancement and lubrication to medical device products, are sold directly to medical customers, or to contract manufacturers employed by these medical customers.

 

 

The Company does have competition in the marketplace for some of its products, particularly its cosmetic ingredients, some of its pharmaceutical products, and its medical lubricants. These competitive products are usually sold at a lower price than the Company’s products; however, they may not compare favorably to the level of performance and quality of the Company’s products.

 

As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, the Company recognizes revenue from sales of its products when those products are shipped, which is when the Company’s performance obligation is satisfied. The Company’s cosmetic ingredients are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of the Company’s non-pharmaceutical medical products are deemed final upon shipment, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective. Sales of the Company’s pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product cannot be sold because it is too close to its expiration date; or (d) the product has expired (but it is not more than one year after the expiration date). This return policy conforms to standard pharmaceutical industry practice. The Company estimates an allowance for outdated material returns based on previous years’ historical returns of its pharmaceutical products.

 

In recent years the Company has elected to rely on trade secret protection to protect its intellectual property for the proprietary product formulations and manufacturing methods. The Company will file for patent protection in situations where the Company believes that relying on trade secret protection alone would not provide sufficient protection. The Company owns the Lubrajel®, Natrajel®, Renacidin®, and Clorpactin® trademarks.

 

CRITICAL ACCOUNTING POLICIES

 

As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, the discussion and analysis of the Company’s financial condition and results of operations are based on its financial statements, which have been prepared in conformity with US GAAP. The preparation of those financial statements required the Company to make estimates and assumptions that affect the carrying value of assets, liabilities, revenues, and expenses reported in those financial statements. Those estimates and assumptions can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition, concentration of credit risk, investments, inventory, and income taxes. Since December 31, 2023, there have been no significant changes to the assumptions and estimates related to those critical accounting policies.

 

The following discussion and analysis cover material changes in the financial condition of the Company since the year ended December 31, 2023, and a comparison of the results of operations for the three and six months ended June 30, 2024 and June 30, 2023. This discussion and analysis should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. All references in this quarterly report to “sales” or “Sales” shall mean Net Sales unless specified otherwise.

 

In accordance with ASU-2016-13, the Company recognizes an allowance for credit losses for financial assets carried at amortized cost to present the net amount expected to be collected as of the balance sheet date. Such allowance is based on the credit losses expected to arise over the life of the asset.

 

RESULTS OF OPERATIONS

 

Net Sales

 

Net sales for the second quarter of 2024 increased by $739,906 (28%) when compared with the same period in 2023. Net sales for the first half of 2024 increased by $1,424,526 (27%) as compared with the corresponding period in 2023. The increase in sales for the second quarter of 2024 and the first half of 2024 were attributable to changes in sales of the following product lines:

 

 

Cosmetic ingredients:

 

(a) Second quarter sales: For the second quarter of 2024, the Company’s sales of cosmetic ingredients increased by $646,487 (84%) when compared with the second quarter of 2023. The increase was due primarily to a net increase of $775,682 (59%) in sales of the Company’s cosmetic ingredients to ASI when compared with the second quarter of 2023. Based on information provided by ASI, the increase in sales was due to two main factors 1) increased demand for the Company’s Lubrajel products in China and 2) the lessening of competition from lower-priced competitors, especially those from Asian producers.

 

Second quarter sales to the Company’s four other distributors, as well as two direct cosmetic ingredient customers, decreased by a net of $129,195 (128%) compared with the second quarter of 2023. The decrease was attributable to sales decreases of $138,439 to the Company’s distributors in the UK and France. These decreases were partially offset by an increase in sales of $9,244 to the Company’s distributors in Italy and Switzerland, as well as two direct customers.

 

(b) Six-month sales: For the first half of 2024 the Company’s sales of cosmetic ingredients increased by $1,761,068 (115%) when compared with the corresponding period in 2023. This increase was due primarily to a net increase in sales to ASI of $1,993,053 (65%) when compared with the first half of 2023. This increase was combined with a net decrease in sales of $231,985 to the Company’s four other distributors and two direct customers. Sales to the Company’s distributors in the United Kingdom, France and Switzerland decreased by $250,917 and sales to the Company’s distributor in Italy, combined with two direct customers, increased by $18,932.

 

Pharmaceuticals:

 

Because there are fees, rebates and allowances associated with sales of the Company’s two pharmaceutical products, Renacidin and Clorpactin WCS-90, discussion of the Company’s pharmaceutical sales includes references to both gross sales (before fees, rebates, and allowances) and net sales (after fees, rebates and allowances).

 

Gross sales of the Company’s pharmaceutical products for the three-month period ended June 30, 2024 increased by $51,888 (3%) compared to the corresponding period in 2023. The increase in gross sales was primarily due to an increase of $73,392 (5%) in gross sales of Renacidin due to customer’s restocking the product after sales were impacted by a short supply of Renacidin in the latter part of 2023 and the beginning of 2024. This increase in gross Renacidin sales for the quarter was offset by a decrease of $21,504 (13%) in gross sales of the Company’s other pharmaceutical product, Clorpactin WCS-90. The decrease in sales of Clorpactin WCS-90 was believed to be caused by normal fluctuations in customer ordering patterns.

 

For the six-month period ended June 30, 2024, gross pharmaceutical sales decreased by $320,960 (10%) compared with the corresponding period in 2023. This decrease was primarily due to the Company’s limited supply of Renacidin during the latter part of 2023 into early March 2024, which resulted in the Company only being able to partially fill many orders. During this period, gross sales of Renacidin decreased by $313,169 (13%). The Company began to fill complete orders of Renacidin towards the end of March 2024. This decrease was also accompanied by a decrease in gross sales of Clorpactin WCS-90 of $7,791 (2%), which was again attributable to normal fluctuations in ordering patterns.

 

Net sales of the Company’s pharmaceutical products for the three- and six-month periods ended June 30, 2024 saw a similar pattern, increasing by $37,063 (3%) for the three-month period and decreasing by $366,838 (13%) for the six-month period, with those decreases due primarily to the reasons noted above.

 

The difference between the change in net sales compared with the change in gross sales for these products is due to a combination of the change in gross sales of those products combined with changes in pharmaceutical sales allowances related to these products. Typically, these allowances have a direct relationship with the sales of the Company’s pharmaceutical products.

 

 

Medical lubricants:

 

Sales of the Company’s medical lubricants for the three- and six-month periods ended June 30, 2024 increased by $74,655 (15%) and $81,763 (9%), respectively, compared with the same periods in 2023. The increase in sales for both the three- and six-month periods was primarily due to an increase in orders from one of the Company’s larger customers in India.

 

Industrial and other products:

 

Sales of the Company's industrial products, as well as other miscellaneous products, for the three- and six-month periods ended June 30, 2024, decreased by $18,299 and $51,467, respectively, when compared with the corresponding periods in 2023. The decrease in sales for both periods was due to the discontinuation of this product line after the second quarter of 2023.

 

Cost of Sales

 

Cost of sales as a percentage of net sales decreased to 46% in the second quarter of 2024 from 54% in the second quarter of 2023. For the first six months of 2024, cost of sales as a percentage of sales decreased to 47% compared with 48% for the first six months of 2023. The decreases in both periods were the result of the product sales mix in 2024 compared with the same periods in 2023. The Company’s cosmetic ingredient sales represented a larger percentage of the Company’s total sales for both the three- and six-month periods ended June 30, 2024 compared with the same periods in 2023. These products carry a higher gross margin than the Company’s pharmaceutical products and lower per unit overhead costs, which was the result of an increase in production of these products due to higher demand in 2024.

 

Operating Expenses

 

Operating expenses, consisting of selling and general and administrative expenses, increased by $28,684 (5%) and $79,603 (7%), respectively, for the three- and six-month periods ended June 30, 2024 compared with the equivalent periods in 2023. The increase in both periods was mainly due an increase in fees paid to the company’s Board of Directors and increases in payroll and payroll-related expenses.

 

Research and Development Expenses

 

Research and development expenses decreased by $17,069 (13%) and $41,046 (16%), respectively, for the three- and six-month periods ended June 30, 2024, compared with the equivalent periods in 2023. The decrease was primarily due to decreases in payroll and payroll-related expenses.

 

Investment Income

 

Investment income increased by $45,057 (82%) for the second quarter of 2024 compared with the second quarter of 2023 and increased by $95,498 (93%) for the first half of 2024 compared with the same period in 2023. The increases in both periods were primarily due to an increase in interest income from investments in United States Treasury Bills compared with the dividend income on the Company’s equity and fixed income mutual funds recorded during the same periods in 2023.

 

This change in the makeup of the investment income was attributable to the Company repositioning its marketable securities portfolio late in the second quarter of 2023. During that time, the Company liquidated most of its holdings of equity and fixed income mutual funds. The Company then used the proceeds from these sales to take advantage of higher interest rates by purchasing U.S. Treasury Bills.

 

 

Net (loss) gain on Marketable Securities

 

The net (loss) gain on marketable securities decreased from a gain of $7,479 for the quarter ended June 30, 2023, to a loss of $9,501 for the quarter ended June 30, 2024. For the six-month periods ended June 30, 2024 and 2023, the net gain on marketable securities decreased from $80,180 to $31,995, respectively. These decreases were primarily due to the factors discussed above regarding the Company’s repositioning of its marketable securities portfolio. For a significant part of the first half of 2023, the Company’s marketable securities’ portfolio was primarily invested in equity and fixed income mutual funds, and in the first half of 2024, these funds were invested primarily in U.S. Treasury Bills, which are considered cash equivalents and the carrying amount approximates fair value due to the short-term nature of the securities. The Company’s management and Board of Directors are continuing to closely monitor the Company's investment portfolio and have made and will continue to make any changes they believe may be necessary or appropriate to minimize the future impact on the Company’s financial position that the volatility of the global financial markets may have.

 

Provision for Income Taxes

 

The Company's effective income tax rate was 21% for the first half and second quarter of both 2024 and 2023. The Company’s tax rate is expected to remain at 21% for the current fiscal year.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Working capital increased from $10,718,457 at December 31, 2023 to $11,429,499 at June 30, 2024, an increase of $711,042. The current ratio decreased from 8.0 to 1 at December 31, 2023 to 7.7 to 1 at June 30, 2024. The increase in working capital was primarily due to an increase in marketable securities and accounts receivable. The decrease in the current ratio was primarily due to an increase in accounts payable.

 

The Company believes that its working capital is, and will continue to be, sufficient to support its operating requirements for at least the next twelve months. The Company intends to utilize its available cash and assets primarily for its continued organic growth and potential future strategic transactions, as well as to mitigate the potential impact of inflation on the Company's business.

 

The Company is in the process of upgrading its building sprinkler system and has incurred costs of $137,000 to date and expects to incur additional costs of $41,000 during the third quarter of 2024. The project is expected to be completed during the third quarter of 2024.

 

The Company generated cash from operations of $1,968,250 and $852,247 for the first half of 2024 and 2023, respectively. The increase from 2023 to 2024 was primarily due to the increase in net income.

 

Net cash used in investing activities was $657,533 in the first half of 2024. Net cash provided by investing activities was $4,800,208 for the first half of 2023. The decrease was due to the sale of the majority of the Company’s equity and fixed income mutual funds during the second quarter of 2023 in order to take advantage of the increase in interest rates. The proceeds from these sales were primarily reinvested in short-term U.S. Treasury Bills, which are included in cash and cash equivalents.         

 

Net cash used in financing activities was $1,148,468 for the first half of 2024. There were no cash flows from financing for the half of 2023. The increase in cash used in financing activities was due to the Company’s Board of Directors changing the Company’s dividend declaration practice in June of 2023. Under the new practice, the Company expects to consider a semi-annual dividend declaration in January and July of each year. On January 30, 2024, the Company’s Board of Directors declared a cash dividend of $0.25 per share, which was paid on February 20, 2024, to all stockholders of record as of February 12, 2024.

 

The Company expects to continue to use its cash to make dividend payments, purchase marketable securities, and take advantage of growth opportunities that are in the best interest of the Company and its shareholders.

 

OFF BALANCE-SHEET ARRANGEMENTS

 

The Company has no off balance-sheet transactions that have, or are reasonably likely to have, a current or future impact on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.

 

 

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

 

The information to be reported under this item is not required of smaller reporting companies.

 

Item 3.         QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

The information to be reported under this item is not required of smaller reporting companies.

 

Item 4.          CONTROLS AND PROCEDURES.

 

(a)

DISCLOSURE CONTROLS AND PROCEDURES

 

The Company’s management, including its Principal Executive Officer and Chief Financial Officer, has evaluated the design, operation, and effectiveness of the Company’s disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (the “Exchange Act”). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon the evaluation performed by the Company’s management, including its Principal Executive Officer and Chief Financial Officer, it was determined that, as of the end of the period covered by this quarterly report, the Company’s disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed in the reports filed or submitted pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding disclosures.

 

(b)

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

 

The Company's Principal Executive Officer and Chief Financial Officer have determined that, during the period covered by this quarterly report, there were no changes in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. They have also concluded that there were no significant changes in the Company’s internal controls after the date of the evaluation.

 

 

PART II - OTHER INFORMATION

ITEM 1.         LEGAL PROCEEDINGS

 

                        NONE

 

ITEM 1A.      RISK FACTORS

 

                    NONE

 

ITEM 2.        UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

                    NONE

 

 

ITEM 3.          DEFAULTS UPON SENIOR SECURITIES

 

                     NONE

 

ITEM 4.          MINE SAFETY DISCLOSURES

 

                     NONE

 

ITEM 5.          OTHER INFORMATION

 

                    NONE

 

ITEM 6.         EXHIBITS

 

31.1*	Certification of Donna Vigilante, President and Principal Executive Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*	Certification of Andrea Young, Chief Financial Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32*	Certifications of Principal Executive Officer and Chief Financial Officer of the Company, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.
101.SCH*	Inline XBRL Taxonomy Extension Schema Document.
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*	Cover Page Interactive Data File (Embedded within the inline XBRL document and included in Exhibit 101.1).

* Filed herewith

 

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	UNITED-GUARDIAN, INC.
	(Registrant)
	By:	/S/ DONNA VIGILANTE
		Donna Vigilante
		President
	By:	/S/ ANDREA YOUNG
Date: August 7, 2024		Andrea Young
		Chief Financial Officer

 

 

 

                                                      

 

EXHIBIT 31.1

 

SECTION 302 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

 

I, Donna Vigilante, certify that:

 

1.	I have reviewed this Quarterly Report of United-Guardian, Inc. on Form 10-Q for the three-month period ended June 30, 2024;

 

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 7, 2024	By:	/s/ Donna Vigilante
		Donna Vigilante
		President and Principal Executive Officer

                                                                                                                       

                                             

EXHIBIT 31.2

 

SECTION 302 CERTIFICATION OF CHIEF FINANCIAL OFFICER

 

I, Andrea Young, certify that:

 

1.	I have reviewed this Quarterly Report of United-Guardian, Inc. on Form 10-Q for the three-month period ended June 30, 2024;

 

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 7, 2024	By:	/s/ Andrea Young
		Andrea Young
		Chief Financial Officer

 

 

EXHIBIT 32

 

 

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the quarterly report of United-Guardian, Inc. (the "Company") on Form 10-Q for the quarterly period ended June 30, 2024, as filed with the Securities and Exchange Commission (the "Report"), I, Donna Vigilante, President and Principal Executive Officer of the Company, and I, Andrea Young, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(i)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(ii)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 7, 2024	By:	/s/ Donna Vigilante
		Donna Vigilante
		President & Principal Executive Officer
	By:	/s/ Andrea Young
		Andrea Young
		Chief Financial Officer

 

        

         

 

 

         

 

 

 

 

 

 

v3.24.2.u1

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2024	Aug. 01, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	1-10526
Entity Registrant Name	UNITED-GUARDIAN, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-1719724
Entity Address, Address Line One	230 Marcus Boulevard
Entity Address, City or Town	Hauppauge
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11788
City Area Code	631
Local Phone Number	273-0900
Title of 12(b) Security	Common Stock, $0.10 par value per share
Trading Symbol	UG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		4,594,319
Entity Central Index Key	0000101295
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false

v3.24.2.u1

Statements of Income (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Net sales	$ 3,390,205	$ 2,650,299	$ 6,645,149	$ 5,220,623
Costs and expenses:
Cost of sales	1,561,090	1,429,407	3,117,580	2,523,002
Operating expenses	602,777	574,093	1,171,642	1,092,039
Research and development	111,660	128,729	214,642	255,688
Total costs and expenses	2,275,527	2,132,229	4,503,864	3,870,729
Income from operations	1,114,678	518,070	2,141,285	1,349,894
Other income (expense):
Investment income	100,007	54,950	198,080	102,582
Net gain on marketable securities	(9,501)	7,479	31,995	80,180
Total other income	90,506	62,429	230,075	182,762
Income before provision for income taxes	1,205,184	580,499	2,371,360	1,532,656
Provision for income taxes	248,959	119,405	489,693	315,481
Net income	$ 956,225	$ 461,094	$ 1,881,667	$ 1,217,175
Earnings per common share
(Basic and Diluted) (in dollars per share)	$ 0.21	$ 0.1	$ 0.41	$ 0.26
Weighted average shares – basic and diluted (in shares)	4,594,319	4,594,319	4,594,319	4,594,319

v3.24.2.u1

Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 8,405,371	$ 8,243,122
Marketable securities	1,453,542	851,318
Accounts receivable, net of allowance for credit losses of $24,321 at March 31, 2024 and $16,672 at December 31, 2023	1,676,957	1,566,839
Inventories (net)	1,172,087	1,223,506
Prepaid expenses and other current assets	220,750	191,708
Prepaid income taxes	213,801	176,220
Total current assets	13,142,508	12,252,713
Deferred income taxes	33,502	50,930
Net property, plant, and equipment:
Land	69,000	69,000
Factory equipment and fixtures	4,698,305	4,669,936
Building and improvements	3,035,512	2,976,577
Total property, plant, and equipment	7,802,817	7,715,513
Less: Accumulated depreciation	7,144,149	7,096,318
Total property, plant, and equipment (net)	658,668	619,195
TOTAL ASSETS	13,834,678	12,922,838
Current liabilities:
Accounts payable	336,879	134,449
Accrued expenses	1,354,753	1,363,044
Deferred revenue	0	15,498
Dividends payable	21,377	21,265
Total current liabilities	1,713,009	1,534,256
Total liabilities	1,713,009	1,534,256
Commitments and Contingencies
Stockholders’ equity:
Common stock $.10 par value; 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at March 31, 2024 and December 31, 2023	459,432	459,432
Retained earnings	11,662,237	10,929,150
Total stockholders’ equity	12,121,669	11,388,582
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 13,834,678	$ 12,922,838

v3.24.2.u1

Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Accounts Receivable, Allowance for Credit Loss, Current	$ 20,241	$ 16,672
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.1	$ 0.1
Common Stock, Shares Authorized (in shares)	10,000,000	10,000,000
Common Stock, Shares, Issued (in shares)	4,594,319	4,594,319
Common Stock, Shares, Outstanding (in shares)	4,594,319	4,594,319

v3.24.2.u1

Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Common Stock, Amount [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022	4,594,319
Balance at Dec. 31, 2022		$ 459,432	$ 8,807,212	$ 9,266,644
Net income			756,081	756,081
Balance (in shares) at Mar. 31, 2023	4,594,319
Balance at Mar. 31, 2023		459,432	9,563,293	10,022,725
Balance (in shares) at Dec. 31, 2022	4,594,319
Balance at Dec. 31, 2022		459,432	8,807,212	9,266,644
Net income				1,217,175
Balance (in shares) at Jun. 30, 2023	4,594,319
Balance at Jun. 30, 2023		459,432	10,024,387	10,483,819
Balance (in shares) at Mar. 31, 2023	4,594,319
Balance at Mar. 31, 2023		459,432	9,563,293	10,022,725
Net income			461,094	461,094
Balance (in shares) at Jun. 30, 2023	4,594,319
Balance at Jun. 30, 2023		459,432	10,024,387	10,483,819
Dividends				0
Balance (in shares) at Dec. 31, 2023	4,594,319
Balance at Dec. 31, 2023		459,432	10,929,150	11,388,582
Net income			925,442	925,442
Dividends		0	(1,148,468)	(1,148,468)
Balance (in shares) at Mar. 31, 2024	4,594,319
Balance at Mar. 31, 2024		459,432	10,706,012	11,165,444
Balance (in shares) at Dec. 31, 2023	4,594,319
Balance at Dec. 31, 2023		459,432	10,929,150	11,388,582
Net income				1,881,667
Balance (in shares) at Jun. 30, 2024	4,594,319
Balance at Jun. 30, 2024		459,432	11,662,237	12,121,669
Dividends	$ 0	0	(112)	(112)
Balance (in shares) at Mar. 31, 2024	4,594,319
Balance at Mar. 31, 2024		459,432	10,706,012	11,165,444
Net income			956,225	956,225
Balance (in shares) at Jun. 30, 2024	4,594,319
Balance at Jun. 30, 2024		$ 459,432	$ 11,662,237	12,121,669
Dividends				$ (112)

v3.24.2.u1

Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals)	6 Months Ended
	Jun. 30, 2024 $ / shares
Common Stock, Dividends, Per Share, Cash Paid (in dollars per share)	$ 0.25

v3.24.2.u1

Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Common Stock, Amount [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022	4,594,319
Balance at Dec. 31, 2022		$ 459,432	$ 8,807,212	$ 9,266,644
Net income			756,081	756,081
Balance (in shares) at Mar. 31, 2023	4,594,319
Balance at Mar. 31, 2023		459,432	9,563,293	10,022,725
Balance (in shares) at Dec. 31, 2022	4,594,319
Balance at Dec. 31, 2022		459,432	8,807,212	9,266,644
Net income				1,217,175
Balance (in shares) at Jun. 30, 2023	4,594,319
Balance at Jun. 30, 2023		459,432	10,024,387	10,483,819
Balance (in shares) at Mar. 31, 2023	4,594,319
Balance at Mar. 31, 2023		459,432	9,563,293	10,022,725
Net income			461,094	461,094
Balance (in shares) at Jun. 30, 2023	4,594,319
Balance at Jun. 30, 2023		459,432	10,024,387	10,483,819
Balance (in shares) at Dec. 31, 2023	4,594,319
Balance at Dec. 31, 2023		459,432	10,929,150	11,388,582
Net income			925,442	925,442
Balance (in shares) at Mar. 31, 2024	4,594,319
Balance at Mar. 31, 2024		459,432	10,706,012	11,165,444
Balance (in shares) at Dec. 31, 2023	4,594,319
Balance at Dec. 31, 2023		459,432	10,929,150	11,388,582
Net income				1,881,667
Balance (in shares) at Jun. 30, 2024	4,594,319
Balance at Jun. 30, 2024		459,432	11,662,237	12,121,669
Balance (in shares) at Mar. 31, 2024	4,594,319
Balance at Mar. 31, 2024		459,432	10,706,012	11,165,444
Net income			956,225	956,225
Balance (in shares) at Jun. 30, 2024	4,594,319
Balance at Jun. 30, 2024		$ 459,432	$ 11,662,237	$ 12,121,669

v3.24.2.u1

Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net income	$ 1,881,667	$ 1,217,175
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	47,831	48,911
Net gain on marketable securities	(31,995)	(80,180)
Gain on sale of equipment	0	(10,000)
Allowance for (recovery of) credit losses	3,569	14,760
Change in allowance for obsolete inventory	(22,000)	8,000
Deferred income taxes	17,428	150,453
(Increase) decrease in operating assets:
Accounts receivable	(113,687)	(127,405)
Inventories	73,419	(115,014)
Prepaid expenses and other current assets	(29,042)	(23,713)
Prepaid income taxes	(37,581)	(210,758)
Increase (decrease) in operating liabilities:
Accounts payable	202,430	125,427
Accrued expenses and other current liabilities	(8,291)	(145,409)
Deferred revenue	(15,498)	0
Net cash provided by operating activities	1,968,250	852,247
us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract
Acquisition of property, plant, and equipment	(87,304)	(3,912)
Proceeds from sale of equipment	0	10,000
Proceeds from sale of marketable securities	775,000	5,255,145
Purchase of marketable securities	(1,345,229)	(461,025)
Net cash used in investing activities	(657,533)	4,800,208
Net cash (used in) provided by investing activities
Dividends paid	(1,148,468)	0
Net cash used in financing activities	(1,148,468)	0
Net (decrease) increase in cash and cash equivalents	162,249	5,652,455
Cash and cash equivalents at beginning of period	8,243,122	830,452
Cash and cash equivalents at end of period	8,405,371	6,482,907
Supplemental disclosure of cash flow information:
Taxes paid	575,795	375,000
Supplemental disclosure of non-cash items:
Dividends payable	$ 112	$ 0

v3.24.2.u1

Note 1 - Nature of Business	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Nature of Business   United-Guardian, Inc. (“Registrant” or “Company”) is a Delaware corporation that, through its Guardian Laboratories division, manufactures and markets cosmetic ingredients, pharmaceutical products, medical lubricants, and sexual wellness ingredients. Prior to July 1, 2023, the Company manufactured and reported sales of a line of specialty industrial products; however, this product line was discontinued after the second quarter of 2023 due to low sales volume with no growth prospects. The Company conducts research and product development leading to commercialization of new premium ingredients for cosmetics and healthcare products. The Company’s research and development department also modifies, refines, and expands the uses for existing products, with the goal of further developing the market for its products. The Company is developing new products using natural and environmentally friendly raw materials, which is a priority for many of the Company’s cosmetic customers.

v3.24.2.u1

Note 2 - Basis of Presentation	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of Presentation   Interim condensed financial statements of the Company are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information, pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments considered necessary for the fair presentation of financial statements for the interim periods have been included. The results of operations for the three and six months ended June 30, 2024 (also referred to as the "second quarter of 2024" and the "first half of 2024", respectively) are not necessarily indicative of results that ultimately may be achieved for any other interim period or for the year ending December 31, 2024. The interim unaudited condensed financial statements and notes thereto should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

v3.24.2.u1

Note 3 - Impact of Global Supply Chain Instability and Inflation	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Impact of Coronavirus (COVID-19) [Text Block]	3. Impact of Global Supply Chain Instability and Inflation   The continued supply chain instability, primarily caused by military conflicts in the Middle East, has impacted vessels’ access to the Red Sea and Suez Canal. The Company is working closely with its suppliers regarding lead times and continues to closely monitor this situation. Although the Company has not experienced any delays in receiving raw materials or a substantial increase in shipping costs, we are aware that the situation is fluid and could impact the Company at any time. If that occurs, we may experience longer lead times and increased shipping costs for some of the Company’s raw materials, which may impact the Company’s future gross margins.   As a result of this global supply chain instability and higher interest rates, there continues to be uncertainty regarding the potential impact on the Company’s operations and financial results and we are unable to provide an accurate estimate or projection as to what the future impact will be.

v3.24.2.u1

Note 4 - Use of Estimates	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Use of Estimates Disclosure [Text Block]	4. Use of Estimates   In preparing financial statements in conformity with Generally Accepted Accounting Principles in the United States of America (“US GAAP”), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for credit losses, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocation of overhead.

v3.24.2.u1

Note 5 - Cash and Cash Equivalents	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Cash and Cash Equivalents Disclosure [Text Block]	5. Cash and Cash Equivalents   For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at the time of purchase. The Company deposits cash and cash equivalents with financially strong, FDIC-insured financial institutions, and believes that any amounts above FDIC insurance limitations are at minimal risk. The amounts held in excess of FDIC limits at any point in time are considered temporary and are primarily due to the timing of the maturities of United States Treasury Bills. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At June 30, 2024 and December 31, 2023, $506,000 and $315,000, respectively, exceeded the FDIC limit.   Cash and cash equivalents include currency on hand, demand deposits with banks or financial institutions, and short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. The following table summarizes the Company's cash and cash equivalents:       June 30,     December 31,       2024     2023   Demand Deposits   $ 1,181,655     $ 340,034   Certificates of Deposit (original maturities of < 3 months)     -       125,000   Money Market Funds     178,770       1,031,361   U.S. Treasury Bills (original 3-month maturity)     7,044,946       6,746,727   Total Cash and Cash Equivalents   $ 8,405,371     $ 8,243,122

v3.24.2.u1

Note 6 - Accounts Receivable and Reserves	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Accounts and Nontrade Receivable [Text Block]	6. Accounts Receivable and Reserves   As of January 1, 2023, the Company adopted FASB Accounting Standards Update (“ASU”) No. 2016-13, Measurement of Credit Losses on Financial Instruments, and all subsequently issued related amendments, which changed the methodology used to recognize impairment of the Company’s contract receivables. Under this ASU, financial assets are presented at the net amount expected to be collected, requiring immediate recognition of estimated credit losses expected to occur over the asset’s remaining life. This is in contrast to previous US GAAP, under which credit losses were not recognized until it was probable that a loss had been incurred. The Company performed its expected credit loss calculation based on historical accounts receivable write-offs, including consideration of then-existing economic conditions and expected future conditions. The adoption of this ASU did not have a significant impact on the financial statements. Prior to the implementation of ASU No. 2016-13, the Company calculated its reserve for accounts receivable by considering many factors including historical data, experience, customer types, credit worthiness and economic trends.   The carrying amount of accounts receivable is reduced by an allowance for credit losses that reflects the Company’s best estimate of the amounts that will not be collected as of the balance sheet date. This allowance is based on the credit losses expected to arise over the life of the asset and is based on the Current Expected Credit Losses (“CECL”). At June 30, 2024, and December 31, 2023, the allowance for credit losses related to accounts receivable amounted to $20,241 and $16,672, respectively.

v3.24.2.u1

Note 7 - Revenue Recognition	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	7. Revenue Recognition   The Company records revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales.   As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, the Company recognizes revenue from sales of its products when those products are shipped, which is when the Company’s performance obligation is satisfied. The Company’s cosmetic ingredients are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of the Company’s non-pharmaceutical medical products are deemed final upon shipment, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective. Sales of the Company’s pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product cannot be sold because it is too close to its expiration date; or (d) the product has expired (but it is not more than one year after the expiration date). This return policy conforms to standard pharmaceutical industry practice. The Company estimates an allowance for outdated material returns based on previous years’ historical returns of its pharmaceutical products.   The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period that the revenues are recognized. Such deductions, primarily related to sales of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with the Company’s participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.   During 2024 and 2023, the Company participated in various government drug rebate programs related to the sale of Renacidin®, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (FSS), and the Medicare Part D Coverage Gap Discount Program (CGDP). These programs require the Company to sell its product at a discounted price. The Company’s sales, as reported, are net of these product rebates and discounts, some of which are estimated and are recorded in the same period that the revenue is recognized.   In August of 2022, the Inflation Reduction Act (“IRA”) was signed into law. The IRA made significant changes to the current Medicare Part D benefit design as it relates to discounts available to enrollees from pharmaceutical manufacturers of brand name drugs. Beginning on January 1, 2025, the Centers for Medicare & Medicaid Services (“CMS”) will implement a new Medicare Part D Manufacturer Discount Program (“discount program”), which will replace the current CGDP. The new discount program eliminates the coverage gap benefit phase, introduces pharmaceutical manufacturer discounts in the initial and catastrophic coverage phases and lowers the cap on enrollee out-of-pocket costs. Under the new discount program, additional rebates are expected to be owed by pharmaceutical manufacturers due to the restructuring of the benefit periods. The overall financial impact of this new program will vary depending on the products being reimbursed but does have the potential to increase Medicare Part D rebates for drug manufacturers. At this time, the Company is unable to predict what future impact this new program will have on its financial condition; however, on January 31, 2024, the Company was notified by CMS that it qualified as a “specified small manufacturer” and will be entitled to a multi-year phase-in period during which it will pay a lower percentage discount on drugs dispensed to beneficiaries.   The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party.   Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606. At June 30, 2024 and December 31, 2023, the Company had an allowance of $268,242 and $247,847, respectively, for possible outdated material returns, which is included in accrued expenses. There is no asset value associated with these outdated material returns, as these products are destroyed.   As of December 31, 2023, the Company recorded advance payments from customers of $15,498, which were included in deferred revenue on the balance sheet. The related performance obligations associated with these payments were satisfied in the first quarter of 2024. There were no such advance payments as of June 30, 2024.   The Company has distribution fee contracts with certain distributors of its pharmaceutical products that entitle them to distribution and service-related fees. The Company records distribution fees and estimates of distribution fees as offsets to revenue.   Disaggregated sales by product class are as follows:         Three months ended     Six months ended       June 30,     June 30,       2024     2023     2024     2023                                     Cosmetic ingredients   $ 1,419,374     $ 772,887     $ 3,295,856     $ 1,534,788   Pharmaceuticals     1,413,664       1,376,601       2,363,987       2,730,825   Medical lubricants     557,167       482,512       985,306       903,543   Industrial products (1)     -       18,299       -       51,467   Total Net Sales   $ 3,390,205     $ 2,650,299     $ 6,645,149     $ 5,220,623               (1) This product line was discontinued as of July 1, 2023.   The Company’s cosmetic ingredients are marketed worldwide by five distributors, of which U.S.-based Ashland Specialty Ingredients (“ASI”) purchases the largest volume. Approximately 17% of the Company’s total sales in the second quarter of 2024 were to customers located outside of the United States, compared with approximately 22% in the second quarter of 2023. For the six months ended June 30, 2024, approximately 15% of the Company’s total sales were to customers located outside of the United States, compared with approximately 23% for the six months ended June 30, 2023.   Disaggregated sales by geographic region are as follows:       Three months ended     Six months ended       June 30,     June 30,       2024     2023     2024     2023   United States*   $ 2,808,237     $ 2,067,533     $ 5,627,173     $ 4,009,775   Other countries     581,968       582,766       1,017,976       1,210,848   Total Sales   $ 3,390,205     $ 2,650,299     $ 6,645,149     $ 5,220,623       * Since substantially all purchases by ASI are shipped to ASI’s warehouses in the U.S., all sales to ASI are reported as U.S. sales for financial reporting purposes, even though a significant quantity of those purchases will be shipped by ASI to foreign customers. ASI has reported to the Company that approximately 85% of its sales of the Company’s products in the second quarter of 2024 were to foreign customers, with China representing approximately 56%. For the same time period in 2023, approximately 65% of ASI’s sales of the Company’s products were to foreign customers, with China representing approximately 35%.   For the six months ended June 30, 2024 approximately 84% of ASI’s sales of the Company’s products were to customers in other countries, with China accounting for approximately 50% of ASI’s sales of the Company’s products, as compared with approximately 68% of ASI’s sales going to customers in other countries for the six months ended June 30, 2023, with China accounting for approximately 29% of ASI’s sales of the Company’s products during that period.

v3.24.2.u1

Note 8 - Accounting for Financial Instruments - Credit Losses	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Credit Loss, Financial Instrument [Text Block]	8. Accounting for Financial Instruments – Credit Losses   The Company recognizes an allowance for credit losses for its trade receivables to present the net amount expected to be collected as of the balance sheet date. This allowance is based on the credit losses expected to arise over the life of the asset and are based on Current Expected Credit Losses (CECL).   The timing between recognition of revenue for product sales and the receipt of payment is not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. The Company provides allowances for any receivables for which collection is doubtful in accordance with ASU 2016-13. As of June 30, 2024 and December 31, 2023, the allowance for credit losses on accounts receivable was $20,241 and $16,672, respectively. Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded only after they have been taken.

v3.24.2.u1

Note 9 - Marketable Securities	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	9. Marketable Securities   The Company’s marketable securities include investments in equity mutual funds and Certificates of Deposit with maturities longer than three months. The Company’s marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. Certificates of Deposit are recorded at amortized cost. Realized gains or losses on mutual funds are determined on a specific identification basis. The Company evaluates its investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and the Company’s ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery of market value.   The disaggregated net gains and losses on marketable securities that were recognized on the income statements for the three and six months ended June 30, 2024 and June 30, 2023 were as follows:       THREE MONTHS ENDED JUNE 30,     SIX MONTHS ENDED JUNE 30,       2024       2023     2024     2023   Net (losses) gains recognized during the period on marketable securities   $ (9,501 )   $ 7,479     $ 31,995     $ 80,180   Less: Net losses recognized on marketable securities sold during the period     -       (433,769 )     -       (433,769 ) Unrealized (losses) gains recognized during the reporting period on marketable securities still held at the reporting date   $ (9,501 )   $ 441,248     $ 31,995     $ 513,949     The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows:   •    Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.   •    Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.   •    Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value measurement.   The Company’s marketable equity securities, which are considered available for sale securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets. The Company’s fixed income Certificates of Deposit are considered held-to-maturity securities and are valued at amortized cost.   The following tables summarize the Company’s investments:   June 30, 2024 (unaudited)                   Unrealized       Cost     Fair value     gain   Equity and other mutual funds   $ 583,103     $ 617,086     $ 33,983                             Other short-term investments:                         Fixed income Certificates of Deposit (original maturities >3 months)     836,456       836,456       -   Total marketable securities   $ 1,419,559     $ 1,453,542     $ 33,983                                       December 31, 2023 (audited)                   Unrealized       Cost     Fair Value     gain   Equity Securities                         Equity and other mutual funds   $ 574,330     $ 576,318     $ 1,988                             Other short-term investments:                         Fixed income Certificates of Deposit (original maturities >3 months)     275,000       275,000       -   Total marketable securities   $ 849,330     $ 851,318     $ 1,988     Investment income is recognized when earned and consists principally of dividend income from equity mutual funds and interest income from United States Treasury Bills, Certificates of Deposit and money market funds. Realized gains and losses on sales of investments are determined on a specific identification basis.   Proceeds from the sale and redemption of marketable securities amounted to $775,000 for the first half of 2024, and there were no realized gains or losses recognized on these sales. Proceeds from the sale and redemption of marketable securities amounted to $5,255,145 for the first half of 2023, which included realized losses on sales of $433,769.

v3.24.2.u1

Note 10 - Inventories	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Inventory Disclosure [Text Block]	10. Inventories       June 30,     December 31,       2024     2023       (unaudited)     (audited)   Inventories consist of the following:                 Raw materials   $ 587,938     $ 476,501   Work in process     74,409       92,089   Finished products     509,740       654,916   Total inventories   $ 1,172,087     $ 1,223,506     Inventories are valued at the lower of cost and net realizable value. Net realizable value is equal to the selling price less the estimated costs of selling and/or disposing of the product. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Finished product inventories at June 30, 2024 and December 31, 2023 are stated net of a reserve of $25,000 and $47,000, respectively, for slow moving and obsolete inventory.

v3.24.2.u1

Note 11 - Income Taxes	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11. Income Taxes   The Company’s tax provision is based on its estimated annual effective tax rate. The Company continues to fully recognize its tax benefits, and as of June 30, 2024 and December 31, 2023, the Company did not have any unrecognized tax benefits. The Company’s provision for income taxes for the three and six months ended June 30, 2024 and 2023, included the following:       Three months ended     Six months ended       June 30,     June 30,       2024     2023     2024     2023   Provision for (benefit from) federal income taxes - current   $ 302,100     $ (81,601 )   $ 472,040     $ 164,778   Provision for state income taxes - current     -       -       225       250   (Benefit from) provision for federal income taxes - deferred     (53,141 )     201,006       17,428       150,453   Total provision for income taxes   $ 248,959     $ 119,405     $ 489,693     $ 315,481

v3.24.2.u1

Note 12 - Defined Contribution Plan	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Retirement Benefits [Text Block]	12. Defined Contribution Plan   The Company sponsors a 401(k) defined contribution plan (“DC Plan”) that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee’s pay that is deferred by the employee. Employees become fully vested in employer matching contributions immediately.   The Company also makes discretionary contributions to each employee's account based on a "pay-to-pay" safe-harbor formula that qualifies the 401(k) Plan under current IRS regulations. Employees become vested in the discretionary contributions as follows: 20% after two years of employment, and 20% for each year of employment thereafter until the employee becomes fully vested after six years of employment.   The Company accrued $54,500 in contributions to the DC Plan for the six months ended June 30, 2024 and 2023, respectively. In the first six months of 2024 and 2023, the Company made discretionary contributions of $109,000 and $94,326, respectively, to the DC Plan. These payments represented the Company’s 2023 and 2022 accrued discretionary contributions, respectively.

v3.24.2.u1

Note 13 - Other Information	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	13. Other Information       June 30,     December 31,   Accrued Expenses   2024 (unaudited)     2023 (audited)   Bonuses   $ 105,000     $ 187,002   Distribution fees     432,602       407,133   Payroll and related expenses     118,356       96,157   Reserve for outdated material     268,242       247,847   Company 401(k) contribution     54,500       109,000   Audit fee     42,128       71,000   Annual report expenses     40,623       81,725   Sales rebates     220,764       132,250   Insurance     42,272       -   Other     30,266       30,930   Total accrued expenses   $ 1,354,753     $ 1,363,044

v3.24.2.u1

Note 14 - Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Accounting Standards Update and Change in Accounting Principle [Text Block]	14. Recent Accounting Pronouncements   In December 2023, the FASB issued ASU 2023-09 “Income Taxes- Improvements to Income Tax Disclosures”. This guidance enhances the transparency and decision usefulness of income tax disclosures. More specifically, the amendments relate to the income tax rate reconciliation and income taxes paid disclosures and require 1) consistent categories and greater disaggregation of information in the rate reconciliation and 2) income taxes paid disaggregated by jurisdiction. This guidance is effective for fiscal years beginning after December 31, 2024.

v3.24.2.u1

Note 15 - Concentration of Credit Risk	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	15. Concentrations of Credit Risk   Customer Concentration: Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether any credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its credit risk from accounts receivable has been reduced.   During the three months ended June 30, 2024, the Company’s largest cosmetic ingredient distributors and three of its pharmaceutical distributors, accounted for 82% of the Company’s gross sales, and 83% of its outstanding accounts receivable at June 30, 2024. During the three months ended June 30, 2023, the same cosmetic ingredient distributor and three pharmaceutical distributors accounted for 72% of the Company’s gross sales and 82% of its outstanding accounts receivable at June 30, 2023.   During the six months ended June 30, 2024, the Company’s largest cosmetic ingredient distributors, along with three of its pharmaceutical distributors, accounted for 82% of the Company’s gross sales and 83% of its outstanding accounts receivable at June 30, 2024. During the six-month period ended June 30, 2023, the same cosmetic ingredient distributor and three pharmaceutical distributors accounted for 73% of the Company’s gross sales and 82% of its outstanding accounts receivable at June 30, 2023.

v3.24.2.u1

Note 16 - Supplier Concentration	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Vendor Concentration Risk Disclosure [Text Block]	16. Supplier Concentration   Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals that available in ample supply from numerous sources. However, there are some raw materials used by the Company that are not readily available or require longer lead times.   During the first half of 2024 and 2023, the Company had three major raw material suppliers that collectively accounted for approximately 79% and 80%, respectively, of the raw material purchases made by the Company. For the three months ended June 30, 2024, the Company had three major raw material suppliers that collectively accounted for approximately 83% of the raw material purchases made by the Company. For the three months ended June 30, 2023, the Company had two major raw material suppliers that collectively accounted for approximately 89% of the raw material purchases made by the Company. In addition to the Company’s raw materials concentration, the Company utilizes one contract manufacturer for the production of its pharmaceutical product, Renacidin. Any disruption in this manufacturer’s operations could have a material impact on the Company’s revenue stream.

v3.24.2.u1

Note 17 - Related-party Transactions	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	17. Related-Party Transactions   For the three- and six-month periods ended June 30, 2024, the Company made payments of $10,000 and $20,000, respectively, to Ken Globus, the Company’s former President, for consulting services provided to the Company. For the three- and six-month periods ended June 30, 2023, the Company made payments of $30,000 and $60,000, respectively, to Ken Globus for consulting services.   For the three- and six-month periods ended June 30, 2024, the Company made payments of $5,250 and $10,750, respectively, to the accounting firm PKF O’Connor Davies (“PKF”) for accounting and tax services. For the three- and six-month periods ended June 30, 2023, the Company made payments of $3,000 to the accounting firm PKF, for accounting and tax services. Lawrence Maietta, a partner at PKF, is a director of the Company.

v3.24.2.u1

Note 18 - Earnings Per Share	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	18. Earnings Per Share   Basic earnings per share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period, increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued.   Per share basic and diluted earnings amounted to $0.21 and $0.10 for the three months ended June 30, 2024 and 2023, respectively, and $0.41 and $0.26 for the six months ended June 30, 2024 and 2023, respectively.

v3.24.2.u1

Note 19 - Dividends	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Dividends [Text Block]	19. Dividends   On January 30, 2024, the Company’s Board of Directors declared a cash dividend of $0.25 per share, which was paid on February 20, 2024, to all holders of record as of February 12, 2024. During the first half of 2024, the Company declared a total of $1,148,580 in dividends, of which $1,148,468 was paid. The balance of $112 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. There were no dividends declared or paid in the first half of 2023.

v3.24.2.u1

Note 20 - Subsequent Events	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	20. Subsequent Events   On July 10, 2024, the Company’s Board of Directors declared a cash dividend of $0.35 per share, which was paid on July 31, 2024, to all holders of record as of July 23, 2024. Dividends totaling $1,607,855 were paid on July 31, 2024, leaving a balance of $156 that was not paid. This $156 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.

v3.24.2.u1

Insider Trading Arrangements	6 Months Ended
	Jun. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	ITEM 5.          OTHER INFORMATION                       NONE
Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

v3.24.2.u1

Note 5 - Cash and Cash Equivalents (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Cash and Cash Equivalents [Table Text Block]	June 30,     December 31,       2024     2023   Demand Deposits   $ 1,181,655     $ 340,034   Certificates of Deposit (original maturities of < 3 months)     -       125,000   Money Market Funds     178,770       1,031,361   U.S. Treasury Bills (original 3-month maturity)     7,044,946       6,746,727   Total Cash and Cash Equivalents   $ 8,405,371     $ 8,243,122

v3.24.2.u1

Note 7 - Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three months ended     Six months ended       June 30,     June 30,       2024     2023     2024     2023                                     Cosmetic ingredients   $ 1,419,374     $ 772,887     $ 3,295,856     $ 1,534,788   Pharmaceuticals     1,413,664       1,376,601       2,363,987       2,730,825   Medical lubricants     557,167       482,512       985,306       903,543   Industrial products (1)     -       18,299       -       51,467   Total Net Sales   $ 3,390,205     $ 2,650,299     $ 6,645,149     $ 5,220,623
Revenue from External Customers by Geographic Areas [Table Text Block]	Three months ended     Six months ended       June 30,     June 30,       2024     2023     2024     2023   United States*   $ 2,808,237     $ 2,067,533     $ 5,627,173     $ 4,009,775   Other countries     581,968       582,766       1,017,976       1,210,848   Total Sales   $ 3,390,205     $ 2,650,299     $ 6,645,149     $ 5,220,623

v3.24.2.u1

Note 9 - Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Gain (Loss) on Securities [Table Text Block]	THREE MONTHS ENDED JUNE 30,     SIX MONTHS ENDED JUNE 30,       2024       2023     2024     2023   Net (losses) gains recognized during the period on marketable securities   $ (9,501 )   $ 7,479     $ 31,995     $ 80,180   Less: Net losses recognized on marketable securities sold during the period     -       (433,769 )     -       (433,769 ) Unrealized (losses) gains recognized during the reporting period on marketable securities still held at the reporting date   $ (9,501 )   $ 441,248     $ 31,995     $ 513,949
Marketable Securities [Table Text Block]	June 30, 2024 (unaudited)                   Unrealized       Cost     Fair value     gain   Equity and other mutual funds   $ 583,103     $ 617,086     $ 33,983                             Other short-term investments:                         Fixed income Certificates of Deposit (original maturities >3 months)     836,456       836,456       -   Total marketable securities   $ 1,419,559     $ 1,453,542     $ 33,983   December 31, 2023 (audited)                   Unrealized       Cost     Fair Value     gain   Equity Securities                         Equity and other mutual funds   $ 574,330     $ 576,318     $ 1,988                             Other short-term investments:                         Fixed income Certificates of Deposit (original maturities >3 months)     275,000       275,000       -   Total marketable securities   $ 849,330     $ 851,318     $ 1,988

v3.24.2.u1

Note 10 - Inventories (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30,     December 31,       2024     2023       (unaudited)     (audited)   Inventories consist of the following:                 Raw materials   $ 587,938     $ 476,501   Work in process     74,409       92,089   Finished products     509,740       654,916   Total inventories   $ 1,172,087     $ 1,223,506

v3.24.2.u1

Note 11 - Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Three months ended     Six months ended       June 30,     June 30,       2024     2023     2024     2023   Provision for (benefit from) federal income taxes - current   $ 302,100     $ (81,601 )   $ 472,040     $ 164,778   Provision for state income taxes - current     -       -       225       250   (Benefit from) provision for federal income taxes - deferred     (53,141 )     201,006       17,428       150,453   Total provision for income taxes   $ 248,959     $ 119,405     $ 489,693     $ 315,481

v3.24.2.u1

Note 13 - Other Information (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	June 30,     December 31,   Accrued Expenses   2024 (unaudited)     2023 (audited)   Bonuses   $ 105,000     $ 187,002   Distribution fees     432,602       407,133   Payroll and related expenses     118,356       96,157   Reserve for outdated material     268,242       247,847   Company 401(k) contribution     54,500       109,000   Audit fee     42,128       71,000   Annual report expenses     40,623       81,725   Sales rebates     220,764       132,250   Insurance     42,272       -   Other     30,266       30,930   Total accrued expenses   $ 1,354,753     $ 1,363,044

v3.24.2.u1

Note 5 - Cash and Cash Equivalents (Details Textual) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Cash, Uninsured Amount	$ 506,000	$ 315,000

v3.24.2.u1

Note 5 - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Certificates of Deposit	$ 0	$ 125,000
Money market funds	178,770	1,031,361
U.S. Treasury Bills (original 3-month maturity)	7,044,946	6,746,727
Total cash and cash equivalents	8,405,371	8,243,122
Demand Deposits [Member]
Demand deposits	$ 1,181,655	$ 340,034

v3.24.2.u1

Note 6 - Accounts Receivable and Reserves (Details Textual) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Accounts Receivable, Allowance for Credit Loss	$ 20,241	$ 16,672

v3.24.2.u1

Note 7 - Revenue Recognition (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Allowance for Material Returns	$ 268,242		$ 268,242		$ 247,847
Contract with Customer, Liability, Current	$ 0		$ 0		$ 15,498
Cosmetic Ingredients [Member] | Non-US [Member] | Geographic Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Percentage	17.00%	22.00%	15.00%	23.00%
ASI [Member] | Non-US [Member] | Geographic Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Percentage	85.00%	65.00%	84.00%	68.00%
ASI [Member] | CHINA | Geographic Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Percentage	56.00%	35.00%	50.00%	29.00%

v3.24.2.u1

Note 7 - Revenue Recognition - Disaggregated Revenue (Details) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Net sales		$ 3,390,205	$ 2,650,299	$ 6,645,149	$ 5,220,623
Cosmetic Ingredients [Member]
Net sales		1,419,374	772,887	3,295,856	1,534,788
Pharmaceuticals [Member]
Net sales		1,413,664	1,376,601	2,363,987	2,730,825
Medical [Member]
Net sales		557,167	482,512	985,306	903,543
Industrial And Other [Member]
Net sales	[1]	$ 0	$ 18,299	$ 0	$ 51,467
[1] (1) This product line was discontinued as of July 1, 2023.

v3.24.2.u1

Note 7 - Revenue Recognition - Revenue by Geographic Region (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Net sales	$ 3,390,205	$ 2,650,299	$ 6,645,149	$ 5,220,623
UNITED STATES
Net sales	2,808,237	2,067,533	5,627,173	4,009,775
Non-US [Member]
Net sales	$ 581,968	$ 582,766	$ 1,017,976	$ 1,210,848

v3.24.2.u1

Note 8 - Accounting for Financial Instruments - Credit Losses (Details Textual) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Accounts Receivable, Allowance for Credit Loss, Current	$ 20,241	$ 16,672

v3.24.2.u1

Note 9 - Marketable Securities (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Proceeds from Sale and Maturity of Marketable Securities			$ 775,000	$ 5,255,145
Debt and Equity Securities, Realized Gain (Loss)	$ 0	$ 433,769	$ 0	$ 433,769

v3.24.2.u1

Note 9 - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Net (losses) gains recognized during the period on marketable securities	$ (9,501)	$ 7,479	$ 31,995	$ 80,180
Less: Net losses recognized during the period on marketable securities sold during the period	0	(433,769)	0	(433,769)
Unrealized (losses) gains recognized during the reporting period on marketable securities still held at the reporting date	$ (9,501)	$ 441,248	$ 31,995	$ 513,949

v3.24.2.u1

Note 9 - Marketable Securities - Summary of Investments (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Equity and other mutual funds, cost	$ 583,103
Equity and other mutual funds, fair value	617,086
Equity and other mutual funds, unrealized gain	33,983
Fixed income certificates of deposit, cost	836,456	$ 275,000
Fixed income certificates of deposit, fair value	836,456	275,000
Fixed income certificates of deposit, unrealized loss	0
Marketable securities, cost	1,419,559	849,330
Marketable securities	1,453,542	851,318
Marketable securities, unrealized loss	$ 33,983	1,988
Equity And Other Mutual Funds [Member]
Equity and other mutual funds, cost		574,330
Equity and other mutual funds, fair value		576,318
Equity and other mutual funds, unrealized gain		$ 1,988

v3.24.2.u1

Note 10 - Inventories (Details Textual) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Inventory Valuation Reserves	$ 25,000	$ 47,000

v3.24.2.u1

Note 10 - Inventories - Summary of Inventories (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Raw materials	$ 587,938	$ 476,501
Work in process	74,409	92,089
Finished products	509,740	654,916
Total inventories	$ 1,172,087	$ 1,223,506

v3.24.2.u1

Note 11 - Income Taxes - Provision for Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Provision for federal income taxes - current	$ 302,100	$ (81,601)	$ 472,040	$ 164,778
Provision for state income taxes - current	0	0	225	250
Provision for (benefit from) federal income taxes – deferred	(53,141)	201,006	17,428	150,453
Total provision for income taxes	$ 248,959	$ 119,405	$ 489,693	$ 315,481

v3.24.2.u1

Note 12 - Defined Contribution Plan (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Defined Contribution Plan, Cost	$ 54,500	$ 54,500
DC Plan [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 109,000	$ 94,326
DC Plan [Member] | Discretionary Contributions Vesting at Two Years [Member]
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage	20.00%
Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year)	2 years
DC Plan [Member] | Discretionary Contributions Vesting Each Additional Year [Member]
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage	20.00%
Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year)	6 years

v3.24.2.u1

Note 13 - Other Information - Summary of Accrued Expenses (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Bonuses	$ 105,000	$ 187,002
Distribution fees	432,602	407,133
Payroll and related expenses	118,356	96,157
Reserve for outdated material	268,242	247,847
Company 401(k) contribution	54,500	109,000
Audit fee	42,128	71,000
Annual report expenses	40,623	81,725
Sales rebates	220,764	132,250
Insurance	42,272	0
Other	30,266	30,930
Total Accrued Expenses	$ 1,354,753	$ 1,363,044

v3.24.2.u1

Note 15 - Concentration of Credit Risk (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Distributor [Member]
Number of Customers	3	3	3	3
Distributors and Marketing Partners [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage	82.00%	72.00%	82.00%	73.00%
Distributors and Marketing Partners [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage	83.00%	82.00%	83.00%	82.00%

v3.24.2.u1

Note 16 - Supplier Concentration (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Number of Vendors	3	2	3	3
Cost of Goods and Service, Product and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Three Raw Material Vendors [Member]
Concentration Risk, Percentage	83.00%		79.00%	80.00%
Cost of Goods and Service, Product and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Two Raw Material Vendors [Member]
Concentration Risk, Percentage		89.00%

v3.24.2.u1

Note 17 - Related-party Transactions (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Previous President and CEO [Member] | Consulting Services [Member]
Related Party Transaction, Amounts of Transaction	$ 10,000	$ 20,000	$ 30,000	$ 60,000
Director [Member] | Accounting and Tax Services [Member]
Related Party Transaction, Amounts of Transaction	$ 5,250	$ 10,750	$ 3,000	$ 3,000

v3.24.2.u1

Note 18 - Earnings Per Share (Details Textual) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share, Basic, Total (in dollars per share)	$ 0.21	$ 0.1	$ 0.41	$ 0.26

v3.24.2.u1

Note 19 - Dividends (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2024
Common Stock, Dividends, Per Share, Declared	$ 0.25
Dividends Declared	$ 1,148,580
Dividends, Paid	1,148,468	$ 0
Dividends payable	$ 112	$ 0	$ 112

v3.24.2.u1

Note 20 - Subsequent Events (Details Textual) - USD ($)			6 Months Ended
	Jul. 31, 2024	Jul. 10, 2024	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2024
Common Stock, Dividends, Per Share, Declared			$ 0.25
Payments of Dividends			$ 1,148,468	$ (0)
Dividends payable			$ 112	$ 0	$ 112
Subsequent Event [Member]
Common Stock, Dividends, Per Share, Declared		$ 0.35
Payments of Dividends	$ 1,607,855
Dividends payable	$ 156

---